Published in Eur J Nucl Med Mol Imaging on September 13, 2017
What future for the myocardial sympathetic innervation imaging? Eur J Nucl Med Mol Imaging (2017) 0.75
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med (2005) 27.36
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med (1996) 12.77
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (1999) 11.26
Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol (2010) 3.21
Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med (1992) 2.56
Regional myocardial sympathetic denervation predicts the risk of sudden cardiac arrest in ischemic cardiomyopathy. J Am Coll Cardiol (2013) 2.16
LMI1195 PET imaging in evaluation of regional cardiac sympathetic denervation and its potential role in antiarrhythmic drug treatment. Eur J Nucl Med Mol Imaging (2012) 1.40
Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. Eur Heart J (2008) 1.32
Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy. Circulation (1988) 1.24
Cardiac sympathetic imaging with mIBG in heart failure. JACC Cardiovasc Imaging (2010) 1.19
Assessment of underlying etiology and cardiac sympathetic innervation to identify patients at high risk of cardiac death. J Nucl Med (2001) 1.02
Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and nonfailing hearts. J Nucl Cardiol (1999) 1.00
Recent developments in heart failure imaging. JACC Cardiovasc Imaging (2010) 0.93
Cardiac neurotransmission SPECT imaging. J Nucl Cardiol (2004) 0.90
Radiolabeled phenethylguanidines: novel imaging agents for cardiac sympathetic neurons and adrenergic tumors. J Med Chem (2007) 0.89
Use of cardiac radionuclide imaging to identify patients at risk for arrhythmic sudden cardiac death. J Nucl Cardiol (2012) 0.88
Myocardial kinetics of carbon-11-meta-hydroxyephedrine: retention mechanisms and effects of norepinephrine. J Nucl Med (1993) 0.88
Evaluation of LMI1195, a novel 18F-labeled cardiac neuronal PET imaging agent, in cells and animal models. Circ Cardiovasc Imaging (2011) 0.86
Multiparametric molecular imaging provides mechanistic insights into sympathetic innervation impairment in the viable infarct border zone. J Nucl Med (2015) 0.85
Biodistribution and radiation dosimetry of LMI1195: first-in-human study of a novel 18F-labeled tracer for imaging myocardial innervation. J Nucl Med (2014) 0.84
Effects of short-term continuous positive airway pressure on myocardial sympathetic nerve function and energetics in patients with heart failure and obstructive sleep apnea: a randomized study. Circulation (2014) 0.84
4-[18F]Fluoro-m-hydroxyphenethylguanidine: a radiopharmaceutical for quantifying regional cardiac sympathetic nerve density with positron emission tomography. J Med Chem (2013) 0.83
Neuronal mapping of the heart with 6-[18F]fluorometaraminol. J Med Chem (1990) 0.83
The mortality effect of metoprolol CR/XL in patients with heart failure: results of the MERIT-HF Trial. Clin Cardiol (1999) 0.83
The role of nuclear imaging in the failing heart: myocardial blood flow, sympathetic innervation, and future applications. Heart Fail Rev (2011) 0.82
Discrepant uptake of the radiolabeled norepinephrine analogues hydroxyephedrine (HED) and metaiodobenzylguanidine (MIBG) in rat hearts. Eur J Nucl Med Mol Imaging (2013) 0.82
Creation of mortality risk charts using 123I meta-iodobenzylguanidine heart-to-mediastinum ratio in patients with heart failure: 2- and 5-year risk models. Eur Heart J Cardiovasc Imaging (2015) 0.81
Synthesis and bioevaluation of [(18)F]4-fluoro-m-hydroxyphenethylguanidine ([(18)F]4F-MHPG): a novel radiotracer for quantitative PET studies of cardiac sympathetic innervation. Bioorg Med Chem Lett (2013) 0.81
Assessment of the 18F-labeled PET tracer LMI1195 for imaging norepinephrine handling in rat hearts. J Nucl Med (2013) 0.81
Retention Kinetics of the 18F-Labeled Sympathetic Nerve PET Tracer LMI1195: Comparison with 11C-Hydroxyephedrine and 123I-MIBG. J Nucl Med (2015) 0.80
Synthesis of high-specific-radioactivity 4- and 6-[18F]fluorometaraminol-PET tracers for the adrenergic nervous system of the heart. Bioorg Med Chem (2001) 0.79
Current Clinical Applications and Next Steps for Cardiac Innervation Imaging. Curr Cardiol Rep (2017) 0.79
123I-MIBG SPECT for Evaluation of Patients with Heart Failure. J Nucl Med (2015) 0.78
The sympathetic nervous system and heart failure. Cardiol Clin (2014) 0.78
Usefulness of cardiac meta-iodobenzylguanidine imaging to identify patients with chronic heart failure and left ventricular ejection fraction <35% at low risk for sudden cardiac death. Am J Cardiol (2015) 0.78
[(18)F]Fluoro-Hydroxyphenethylguanidines: Efficient Synthesis and Comparison of Two Structural Isomers as Radiotracers of Cardiac Sympathetic Innervation. ACS Chem Neurosci (2017) 0.77
Cardiac retention of PET neuronal imaging agent LMI1195 in different species: impact of norepinephrine uptake-1 and -2 transporters. Nucl Med Biol (2013) 0.77
A novel electrophilic synthesis and evaluation of medium specific radioactivity (1R,2S)-4-[18F]fluorometaraminol, a tracer for the assessment of cardiac sympathetic nerve integrity with PET. Nucl Med Biol (2004) 0.77
High specific radioactivity (1R,2S)-4-[(18)F]fluorometaraminol: a PET radiotracer for mapping sympathetic nerves of the heart. Nucl Med Biol (2000) 0.77
Cardiac molecular imaging. Semin Nucl Med (2014) 0.77
Recent Advances and Clinical Applications of PET Cardiac Autonomic Nervous System Imaging. Curr Cardiol Rep (2017) 0.76
Prediction of all-cause death using (11)C-hydroxyephedrine positron emission tomography in Japanese patients with left ventricular dysfunction. Ann Nucl Med (2016) 0.76
Practical Aspects of 18F-FDG PET When Receiving 18F-FDG from a Distant Supplier. J Nucl Med Technol (2009) 0.76
Mechanistic Insights into Sympathetic Neuronal Regeneration: Multitracer Molecular Imaging of Catecholamine Handling After Cardiac Transplantation. Circ Cardiovasc Imaging (2015) 0.76
Relative uptake, metabolism, and beta-receptor binding of (1R,2S)-4-(18)F-fluorometaraminol and (123)I-MIBG in normotensive and spontaneously hypertensive rats. J Nucl Med (2002) 0.76
Preclinical evaluation of 18F-LMI1195 for in vivo imaging of pheochromocytoma in the MENX tumor model. J Nucl Med (2013) 0.76
11C-meta-hydroxyephedrine: a promising PET radiopharmaceutical for imaging the sympathetic nervous system. Clin Nucl Med (2015) 0.76
Synthesis and evaluation of 4-[18F]fluoropropoxy-3-iodobenzylguanidine ([18F]FPOIBG): A novel 18F-labeled analogue of MIBG. Nucl Med Biol (2015) 0.76
Chemistry and biology of radiotracers that target changes in sympathetic and parasympathetic nervous systems in heart disease. J Nucl Med (2015) 0.76
Myocardial Kinetics of a Novel [(18)F]-Labeled Sympathetic Nerve PET Tracer LMI1195 in the Isolated Perfused Rabbit Heart. JACC Cardiovasc Imaging (2015) 0.76
Metabolic fate of the heart agent [18F]6-fluorometaraminol. Int J Rad Appl Instrum B (1989) 0.76
6-[18F]fluorometaraminol: a radiotracer for in vivo mapping of adrenergic nerves of the heart. J Med Chem (1988) 0.75